Molecular signatures of inherited and acquired sporadic late onset nemaline myopathies.
ACTA1
Histology
NEB
Nemaline myopathy
Proteomics
RNA-seq
Transcriptomics
Journal
Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673
Informations de publication
Date de publication:
26 01 2023
26 01 2023
Historique:
received:
20
12
2022
accepted:
18
01
2023
entrez:
26
1
2023
pubmed:
27
1
2023
medline:
31
1
2023
Statut:
epublish
Résumé
Acquired sporadic late onset nemaline myopathy (SLONM) and inherited nemaline myopathy (iNM) both feature accumulation of nemaline rods in muscle fibers. Unlike iNM, SLONM is amenable to therapy. The distinction between these disorders is therefore crucial when the diagnosis remains ambiguous after initial investigations. We sought to identify biomarkers facilitating this distinction and to investigate the pathophysiology of nemaline rod formation in these different disorders. Twenty-two muscle samples from patients affected by SLONM or iNM underwent quantitative histological analysis, laser capture microdissection for proteomic analysis of nemaline rod areas and rod-free areas, and transcriptomic analysis. In all iNM samples, nemaline rods were found in subsarcolemmal or central aggregates, whereas they were diffusely distributed within muscle fibers in most SLONM samples. In SLONM, muscle fibers harboring nemaline rods were smaller than those without rods. Necrotic fibers, increased endomysial connective tissue, and atrophic fibers filled with nemaline rods were more common in SLONM. Proteomic analysis detected differentially expressed proteins between nemaline rod areas and rod-free areas, as well as between SLONM and iNM. These differentially expressed proteins implicated immune, structural, metabolic, and cellular processes in disease pathophysiology. Notably, immunoglobulin overexpression with accumulation in nemaline rod areas was detected in SLONM. Transcriptomic analysis corroborated proteomic findings and further revealed substantial gene expression differences between SLONM and iNM. Overall, we identified unique pathological and molecular signatures associated with SLONM and iNM, suggesting distinct underlying pathophysiological mechanisms. These findings represent a step towards enhanced diagnostic tools and towards development of treatments for SLONM.
Identifiants
pubmed: 36703211
doi: 10.1186/s40478-023-01518-9
pii: 10.1186/s40478-023-01518-9
pmc: PMC9878979
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20Informations de copyright
© 2023. The Author(s).
Références
Nat Genet. 1995 Jan;9(1):75-9
pubmed: 7704029
Exp Cell Res. 2005 Nov 1;310(2):434-44
pubmed: 16181627
Acta Neuropathol Commun. 2016 Feb 03;4:8
pubmed: 26842778
Skelet Muscle. 2020 Mar 9;10(1):6
pubmed: 32151276
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Acta Neuropathol Commun. 2022 Feb 8;10(1):17
pubmed: 35135626
Genet Test Mol Biomarkers. 2018 Jun;22(6):374-383
pubmed: 29924655
Acta Neuropathol Commun. 2022 Dec 17;10(1):185
pubmed: 36528760
J Neuropathol Exp Neurol. 2020 Aug 1;79(8):908-914
pubmed: 32607581
N Engl J Med. 2006 Mar 30;354(13):1362-9
pubmed: 16571879
Front Behav Neurosci. 2016 Mar 11;10:46
pubmed: 27014007
Amyloid. 2009 Mar;16(1):1-8
pubmed: 19291508
Acta Neuropathol Commun. 2014 Apr 12;2:44
pubmed: 24725366
Muscle Nerve. 2013 Dec;48(6):983-8
pubmed: 23873431
Neuromuscul Disord. 2021 Oct;31(10):955-967
pubmed: 34561123
Neurol Genet. 2019 Jun 04;5(4):e341
pubmed: 31321302
J Proteome Res. 2009 Aug;8(8):3872-81
pubmed: 19522537
J Muscle Res Cell Motil. 2019 Jun;40(2):111-126
pubmed: 31228046
Nat Cell Biol. 2000 Sep;2(9):628-36
pubmed: 10980704
Proc Natl Acad Sci U S A. 1987 Aug;84(15):5262-6
pubmed: 3474653
Neurology. 2014 Dec 2;83(23):2133-9
pubmed: 25378674
Neurol Genet. 2021 May 18;7(3):e590
pubmed: 34235269
Int J Cancer. 2021 Jun 1;148(11):2807-2814
pubmed: 33529362
Hum Mutat. 2013 Jul;34(7):953-60
pubmed: 23568759
Antibodies (Basel). 2019 Apr 11;8(2):
pubmed: 31544835
Rev Neurol (Paris). 2016 Oct;172(10):614-619
pubmed: 27659899
Front Neurol. 2021 Jun 15;12:660113
pubmed: 34211429
Neuromuscul Disord. 1993 Sep-Nov;3(5-6):557-60
pubmed: 8186711
JAMA Neurol. 2022 Aug 1;79(8):808-816
pubmed: 35696196
J Clin Neurosci. 2018 Jul;53:261-262
pubmed: 29731279
Hum Mol Genet. 2019 Aug 1;28(15):2549-2560
pubmed: 30986853
J Exp Med. 2020 Jul 6;217(7):
pubmed: 32441762
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Neurology. 2019 Jul 16;93(3):e298-e305
pubmed: 31167932
Blood. 2017 Jan 19;129(3):299-306
pubmed: 27856462
Neurol Neuroimmunol Neuroinflamm. 2022 May 17;9(4):
pubmed: 35581006
Orphanet J Rare Dis. 2017 May 11;12(1):86
pubmed: 28490364
J Proteome Res. 2007 Feb;6(2):654-61
pubmed: 17269722
J Proteome Res. 2010 Aug 6;9(8):4295-305
pubmed: 20586475
JCI Insight. 2022 Jan 25;7(2):
pubmed: 34874916
Neuromuscul Disord. 2013 Dec;23(12):992-7
pubmed: 24095155
Dev Med Child Neurol. 2020 Mar;62(3):297-302
pubmed: 31578728
Neuropathol Appl Neurobiol. 2017 Feb;43(1):5-23
pubmed: 27976420
Acta Neuropathol Commun. 2021 Apr 29;9(1):79
pubmed: 33926564
Ann Clin Transl Neurol. 2022 Mar;9(3):391-402
pubmed: 35187860
Genet Med. 2019 Jul;21(7):1629-1638
pubmed: 30467404
Cells. 2022 Apr 30;11(9):
pubmed: 35563815
J Neuropathol Exp Neurol. 2010 May;69(5):429-41
pubmed: 20418783
Cell Motil Cytoskeleton. 2008 Dec;65(12):945-54
pubmed: 18792955
J Proteome Res. 2015 Apr 3;14(4):1957-67
pubmed: 25734799
Neuromuscul Disord. 2021 Nov;31(11):1154-1160
pubmed: 34172358
Brain Pathol. 2021 May;31(3):e12962
pubmed: 34043258
Elife. 2017 Aug 09;6:
pubmed: 28826497
Neuromuscul Disord. 2022 Mar;32(3):245-254
pubmed: 35249790
Neurology. 2005 Oct 25;65(8):1158-64
pubmed: 16148261